Summary Twelve patients were treated with didox, a new ribonucleotide reductase inhibitor, by 36 h infusion. The maximum tolerated dose was 6 g m2, above which dose-limiting hepatic toxicity was observed. Patient (Turner et al., 1968) .
following the prolonged infusion. Clearance was higher following the 36 h infusion: 97.6 versus 24.4 1 h-'.
The enzyme ribonucleotide reductase provides an excellent target for anti-cancer drugs in view of the importance of the production of deoxyribonucleotides for DNA synthesis (Elford et al., 1981) . The enzyme is known to have low activity in resting cells, and increasing with proliferation (Elford et al., 1970) , with the level of the enzyme correlated with the rate of replication (Turner et al., 1968) .
Hydroxyurea is a specific inhibitor of ribonucleotide reductase (Thurman, 1964) and is the only inhibitor available clinically at present, although it is a relatively weak inhibitor of the enzyme in vitro (Elford, 1968) . Recently, many hydroxyurea analogues have been tested in vivo and in vitro with didox (N, 3-4 trihydroxybenzamide) exhibiting activity in L1210 leukaemia bearing mice (van't Riet et al., 1979) and in the NCI tumour panel (Elford & van't Riet, 1985) .
Didox causes greater inhibition of the target enzyme (Elford et al., 1979) and in view of its in vivo activity was entered in phase I evaluation, as part of a co-ordinated programme under the aegis of the Cancer Research Campaign Phase I/II Clinical Trials Committee. It was initially administered by intravenous infusion over 30 min (Veale et al., 1988b) . Dose limiting toxicity was predominantly hepatic in these patients and was seen at doses of 7 g m-2 and above. However, at doses greater than 2.3 g m2 significant gastrointestinal toxicity was observed, with severe nausea, vomiting and diarrhoea seen in some patients. The recommended maximum tolerated dose was therefore 6 g m-2. Hydroxyurea has been given safely by infusion over 24-36 h infusion (Veale et al., 1988a) , and didox was therefore administered by 36 h infusion in a phase I study in an attempt to cause more prolonged inhibition of ribonucleotide reductase. De Analytical methods Didox levels were measured in plasma and urine by HPLC using a Beckman/Altex IOOA pump and stainless steel column (15 cm x 0.46 cm) packed with a A-Bondapack C18, 10 jim particle size, as previously described (Veale et al., 1988) . Metabolites were identified using standards supplied by Elford. In order to resolve didox and its metabolites from interfering substances in plasma the following step-gradient system was employed: (1) 0.1 M sodium phosphate pH 6.0 for 2 min; (2) as above + 2% acetonitrile pH 6.0 for 2 min; (3) as above + 5% acetonitrile pH 6.0 for 4 min; (4) as above + 10% acetonitrile pH 6.0 for 0.5 min; (5) as above + 20% acetonitrile pH 6.0 for 0.5 min; (6) Ltd., 1990 Br. J. Cancer (1990 , 61, [447] [448] [449] [450] buffer 1 for 7 min before loading the next sample.
Retention times of 4 min, 7.78 min, 9.5 min, 10.45 min and 12.86 min were observed for didox, amide, 3-OH, 3-MeO and I.S. respectively. Extraction efficiency was 80%, 82%, 95%, 94% for didox, amide, 3-hydroxy and 3-methoxy metabolites, with a detection limit of 100 ng for each compound. Urine samples were injected directly onto the column and eluted isocratically with 0.1 M sodium phosphate pH 6.0. The resolution of metabolites in urine was not possible due to the large number of interfering substances.
The area under the plasma concentration -time curve (AUC) was calculated by the log trapezoidal rule with extrapolation to infinity. As the drug was proven subsequently to have non-linear pharmacokinetics, it was not deemed logical to fit the data to linear compartmental models. Drug clearance was calculated using the expression:
Patient details are shown in Table I . In the 36 h infusion dose escalation study, three patients received 2.5 g m-2, three 5 g m-2, ten 6 g m-2, and two 7 g m-2 of didox. In addition, five patients were treated at 6 g m-2 as a 30 min infusion as part of the comparative pharmacokinetic study. No responses were seen at any dose level.
Details of toxicity are shown in Table II (± s.e.m.) for the parent drug following the 30 min infusion was significantly higher (282 ± 60 versus 68 ± 11 ,ug ml-' h-'). In contrast, AUC levels for the 3-hydroxy metabolite of didox were significantly higher following the prolonged infusion (55.4 ± 3.2 versus 18.6 ± 2.6 Lg ml-' h-'). Gastrointestinal toxicity was severe with the short injection at 6g m-2, although minor hepatotoxicity was also noted.
The recommended maximum tolerated dose for both routes of administration was 6 g m2, although the toxicity profile was different for the two modes of administration. Despite marked differences in pharmacokinetics and drug metabolism between the injection and infusion, the maximum tolerated dose of the drug was the same, with hepatotoxicity doselimiting in both. However, the prolonged infusion was significantly better tolerated and in particular gastrointestinal toxicity was rare.
In a previous study (Veale et al., 1988b) didox was given as a short injection in doses up to 10 g m2. Pharmacokinetics were performed at 1,728 mg m2 in that study, showing ahalf life of 5.2 min, P-half life of 41.3 min and clearance of 42.6 ± 11.4 1 h-1. Although the infusion rates were different in both studies (short infusion versus 30 min) this is unlikely to produce a difference in pharmacokinetics and was accounted for in calculations. Thus clearance showed a marked difference between the two different doses. It is possible that the pharmacokinetics of didox are non-linear as drug clearance is dose-dependent. The ideal way to test this hypothesis is by performing pharmacokinetic studies at each dose level for a schedule, but this was not performed in the present study.
Clearance was also schedule-dependent. It is possible that the increase in clearance of the parent drug seen on increasing the duration of infusion from 0.5 to 36 h could be related to induction of its own metabolism, but this would not explain the reduction in clearance caused by increasing drug dose administered by similar infusion rates. Similarly, the rapid appearance of the amide metabolite within 30 min of the bolus, and the high proportion of 3-hydroxy metabolite within 2 h of starting the infusion, make induced metabolism unlikely.
Interesting differences in the pattern of metabolism were noted on comparing the two infusion rates at 6 g m2. Higher AUC values were seen for the parent drug following the short infusion but higher AUC values for the 3-hydroxy metabolite following the prolonged infusion. An amide metabolite was only detectable following the 30 min infusion. The higher AUC value, higher peak plasma level, lower clearance and altered metabolic profile following the 30 min infusion are suggestive, but not conclusive, that there is saturable hepatic metabolism of didox, with greater production of the 3-hydroxy metabolite when given by the prolonged infusion. Despite these differences in metabolism and pharmacokinetics, the maximum tolerated dose and hepatotoxicity were similar for both infusional rates. Differences in gastrointestinal toxicity may be attributable to the higher peak plasma levels of didox observed following the short infusion. As previously stated, the urinary excretion data is incomplete, as multiple interfering peaks were observed in urine where the metabolite peaks were expected. Therefore, the contribution of various metabolites to total urinary excretion could not be adequately assessed.
Steady state plasma levels of didox of 2.8 ± 1.3 tg ml' were therefore achieved during the 36 h infusion. These levels are slightly lower than those shown to be active in experimental models. In an enzyme study 8.4figml-' didox was shown to cause 50% inhibition of ribonucleotide reductase, and levels of less than 30ggml-' have been growth inhibitory in vitro using a variety of cell lines. Peak achievable plasma levels are, therefore, significantly lower than the levels of didox shown to be effective in vitro. However, the development of toxicity suggests either the metabolites are active, or there are other mechanisms of action in vivo.
The maximum tolerated dose of didox has been shown to be 6 g m-2 by two different schedules. The choice of optimal schedule remains debatable, although the cytostatic activity of didox is related to both the concentration of drug achieved and the duration of exposure. Although Cmax was higher with the short infusion, levels considered adequate to block ribonucleotide reductase were achieved for only a short period. Clearly, it would be possible to design a loading dose/ constant infusion schedule using an intermediate infusion duration that would result in higher steady state levels, albeit for a shorter time. In general, anti-metabolites or drugs acting on S phase targets are more effective given over the duration of a cell cycle rather than for a much shorter period of time. As there was no myelotoxicity observed in these studies, it may be possible to administer didox more frequently than described in this particular schedule, although this would need to be evaluated in a further study. However, this schedule represents the tolerable dose over 36 h and represents a rational duration of infusion, based on our previous data with the S phase specific ribonucleotide reductase inhibitor hydroxyurea (Veale et al., 1988a) .
No responses were seen in this study, although a limited number of patients with refractory tumours were treated. Whether the lack of clinical response relates to the refractory nature of the tumours treated or to the inadequate plasma levels achieved in this study remains unanswered. However, it is intended to carry out a phase II study of didox in patients with breast cancer in the near future, to determine clinical anti-tumour activity.
